Celyad Oncology (Celyad Oncology) Days Payable : 0.00 (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology Days Payable?

Celyad Oncology's average Accounts Payable for the three months ended in Jun. 2023 was $4.37 Mil. Celyad Oncology's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.00 Mil.

The historical rank and industry rank for Celyad Oncology's Days Payable or its related term are showing as below:

During the past 12 years, Celyad Oncology's highest Days Payable was 1151392.50. The lowest was 1974.70. And the median was 7213.62.

CYADY's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 154.12
* Ranked among companies with meaningful Days Payable only.

Celyad Oncology's Days Payable stayed the same from Dec. 2021 (0.00) to Jun. 2023 (0.00). stayed the same

Celyad Oncology Days Payable Historical Data

The historical data trend for Celyad Oncology's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Days Payable Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Celyad Oncology's Days Payable

For the Biotechnology subindustry, Celyad Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Days Payable distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Days Payable falls into.

Celyad Oncology Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Celyad Oncology's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (7.47	+	5.034)	/	2 )	/	0	*	365
=	6.252					/	0	*	365
=	N/A

Celyad Oncology's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (5.034	+	3.696)	/	2 )	/	0	*	365 / 4
=	4.365					/	0	*	365 / 4
=	N/A

Celyad Oncology Days Payable Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (Celyad Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.